title: Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
abstract: Although iron chelation therapy with deferoxamine (DFO) results in improved life expectancy of patients with thalassemia, compliance with parenteral DFO treatment is unsatisfactory, underlining the need for alternative drugs and innovative ways of drug administration. We examined the chelating potential of pyridoxal isonicotinoyl hydrazone (PIH) analogs, alone or in combination with DFO, using hypertransfused rats with labeled hepatocellular iron stores and cultured iron-loaded rat heart cells. Our in vivo studies using 2 representative PIH analogs, 108-o and 109-o, have shown that PIH analogs given orally are 2.6 to 2.8 times more effective in mobilizing hepatocellular iron in rats, on a weight-per-weight basis, than parenteral DFO administered intraperitoneally. The combined effect of DFO and 108-o on hepatocellular iron excretion was additive, and response at a dose range of 25 to 200 mg/kg was linear. In vitro studies in heart cells showed that DFO was more effective in heart cell iron mobilization than all PIH analogs studied. Response to joint chelation with DFO and PIH analogs was similar to an increase in the equivalent molar dose of DFO alone, rather than the sum of the separate effects of the PIH analog and DFO. This finding was most likely the result of iron transfer from PIH analogs to DFO, a conclusion supported directly by iron-shuttle experiments using fluorescent DFO. These findings provide a rationale for the combined, simultaneous use of iron-chelating drugs and may have useful, practical implications for designing novel strategies of iron chelation therapy.
authors.affiliation: Department of Human Nutrition and Metabolism, Hebrew University Hadassah Medical School, Jerusalem, Israel.
authors.forename: Gabriela
authors.initials: G
authors.lastname: Link
authors.forename: Prem
authors.initials: P
authors.lastname: Ponka
authors.forename: Abraham M
authors.initials: AM
authors.lastname: Konijn
authors.forename: William
authors.initials: W
authors.lastname: Breuer
authors.forename: Z Ioav
authors.initials: ZI
authors.lastname: Cabantchik
authors.forename: Chaim
authors.initials: C
authors.lastname: Hershko
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001803:Blood Transfusion; D002478:Cells, Cultured; D003676:Deferoxamine / Q000494:pharmacology*; D005260:Female; D005293:Ferritins / Q000378:metabolism; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000494:pharmacology*; D007504:Iron Radioisotopes; D007538:Isoniazid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D007700:Kinetics; D011730:Pyridoxal / Q000031:analogs & derivatives* / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D007502:Iron Chelating Agents; D007504:Iron Radioisotopes; D011730:Pyridoxal; C021079:pyridoxal isonicotinoyl hydrazone; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine; D007538:Isoniazid